Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2011 Financial Results
Date:11/2/2011

NEW YORK, Nov. 2, 2011 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease (the "Company"), today announced its results for the third quarter ended September 30, 2011.

At September 30, 2011, the Company had cash, cash equivalents, interest receivable and investment securities of $47.2 million.  During the third quarter ended September 30, 2011, the Company received approximately $1.8 million in proceeds from the exercise of stock options.

The net loss for the third quarter ended September 30, 2011 was $10.2 million, or $0.15 per share, compared to a net loss of $5.8 million, or $0.10 per share, for the third quarter in 2010, representing an increase in net loss of $4.4 million.  Other research and development expenses for the third quarter ended September 30, 2011, increased by $4.7 million, as compared to the third quarter of 2010, principally related to the KRX-0401 (perifosine) and Zerenex Phase 3 clinical programs.  The net loss for the third quarter ended September 30, 2011, included $0.5 million of non-cash compensation expense related to equity incentive grants.

The net loss for the nine months ended September 30, 2011 was $19.7 million, or $0.30 per share, compared to a net loss of $15.0 million, or $0.26 per share, for the comparable period in 2010, representing an increase in net loss of $4.7 million.  The nine months ended September 30, 2011 included license revenue of $5.0 million related to a milestone payment from the Company's Japanese partner for Zerenex (ferric citrate), Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd., for their commencement of a Phase 3 clinical program of ferric citrate in J
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. to Host Conference Call on Third Quarter 2011 Financial Results
2. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
3. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2011 Financial Results
4. Keryx Biopharmaceuticals, Inc. to Host Conference Call on Second Quarter 2011 Financial Results
5. Keryx Biopharmaceuticals, Inc. Prices Common Stock Offering
6. Keryx Biopharmaceuticals Announces Commencement of Phase 3 Program of Ferric Citrate (Zerenex™) in Japan by Partner, Japan Tobacco and Torii Pharmaceutical
7. Keryx Biopharmaceuticals Announces Two Poster Presentations on KRX-0401 (Perifosine) at Upcoming American Association for Cancer Research (AACR) Annual Meeting
8. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2010 Financial Results
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year End 2010 Financial Results on Wednesday, March 9, 2011 at 8:30 a.m. ET
10. Keryx Biopharmaceuticals Announces Oral Presentation of Final Zerenex™ Short-Term Phase 3 Data at the Upcoming National Kidney Foundations 2011 Spring Clinical Meetings
11. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... Kingdom , Oct. 30, 2014 Molecular ... CBRX ) and Maryland ... developers with improved efficiency during clinical development that will ... next week. This partnership extends ... platform, which it launched earlier this month. The company ...
(Date:10/30/2014)... Oct. 30, 2014   Auxilium Pharmaceuticals , ... integrated specialty biopharmaceutical company, today announced financial results ... The Company highlighted important corporate, commercial, regulatory and ... "We are very pleased with the continued ... products in our portfolio this quarter, especially the ...
(Date:10/30/2014)... 30, 2014 Today, DripDrop, the first ... it was awarded a two-year contract, effective Sept. ... that serves the more than 100,000 members and ... and Provista.  DripDrop also received ... member hospitals who attended the recent Novation 2014 ...
Breaking Medicine Technology:Molecular Profiles To Launch US Strategic Alliance At AAPS 2Molecular Profiles To Launch US Strategic Alliance At AAPS 3Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 2Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 3Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 4Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 5Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 6Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 7Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 8Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 9Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 10Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 11Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 12Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 13Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 14Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 15Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 16Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 17Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 18Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 19Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 20Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 21Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 22DripDrop Partners With Novation To Help Hospitals Address I.V. Saline Solution Shortages; ORS Product Used For Ebola Outbreak 2DripDrop Partners With Novation To Help Hospitals Address I.V. Saline Solution Shortages; ORS Product Used For Ebola Outbreak 3DripDrop Partners With Novation To Help Hospitals Address I.V. Saline Solution Shortages; ORS Product Used For Ebola Outbreak 4
... 27, 2011 Inovio Pharmaceuticals, Inc. (NYSE Amex: ... synthetic immunogens against cancers and infectious diseases, announced today ... Development Agreement (CRADA) with the United States Department of ... Animal Disease Center. This collaboration will evaluate the efficacy ...
... Co., Inc. (NYSE Amex: TPI ), a pharmaceutical ... branded generics and other pharmaceuticals, announced the financial results for ... year 2011 ending June 30 ... delivered $95.2 million, exceeding the guided $90.0 million revenue forecast ...
Cached Medicine Technology:Inovio Pharmaceuticals Enters Collaboration With U.S. Dept. of Homeland Security to Assess Foot & Mouth Disease Synthetic Vaccines' Potential to Help Ensure Nation's Food Supply Safety 2Inovio Pharmaceuticals Enters Collaboration With U.S. Dept. of Homeland Security to Assess Foot & Mouth Disease Synthetic Vaccines' Potential to Help Ensure Nation's Food Supply Safety 3Inovio Pharmaceuticals Enters Collaboration With U.S. Dept. of Homeland Security to Assess Foot & Mouth Disease Synthetic Vaccines' Potential to Help Ensure Nation's Food Supply Safety 4TPI Reports Fiscal Year 2011 Financial Results 2TPI Reports Fiscal Year 2011 Financial Results 3TPI Reports Fiscal Year 2011 Financial Results 4TPI Reports Fiscal Year 2011 Financial Results 5TPI Reports Fiscal Year 2011 Financial Results 6TPI Reports Fiscal Year 2011 Financial Results 7TPI Reports Fiscal Year 2011 Financial Results 8TPI Reports Fiscal Year 2011 Financial Results 9TPI Reports Fiscal Year 2011 Financial Results 10TPI Reports Fiscal Year 2011 Financial Results 11
(Date:10/30/2014)... model developed by NIH grantees predicts that women must ... infection via vaginal sex, whereas just two doses per ... sex. This finding helps explain why two large clinical ... failed to show efficacy. Participants in the VOICE ... tenofovir (another antiretroviral) for HIV prevention were counseled to ...
(Date:10/30/2014)... Don Allred Insurance, a leading provider ... for North Carolina residents, is excited to announce the ... Hill Mall. The new branch has been up and ... through all facets of the insurance selection process from ... Scott Allred couldn’t be happier with the timing of ...
(Date:10/30/2014)... 30, 2014 Paramount Rx, a full-service ... increasing efforts to help people save money through its ... increase for prescription drugs in the new health care ... resources to bridge the relationship between consumers, businesses and ... biggest challenges people face today with medical costs is ...
(Date:10/30/2014)... Dennis Thompson HealthDay Reporter ... outbreak in Liberia -- one of three West African nations ... Organization officials said Wednesday. Dr. Bruce Aylward, WHO,s assistant ... of burials in Liberia and no increase in laboratory-confirmed cases. ... to tame the epidemic may be making some progress, ...
(Date:10/30/2014)... Francisco, California (PRWEB) October 30, 2014 ... billion by 2020, according to a new study by ... coupled with surging demand for sugar and fat free ... to augment the demand for prebiotics over the forecast ... http://www.grandviewresearch.com/industry-analysis/prebiotics-market , Food & beverage was the ...
Breaking Medicine News(10 mins):Health News:Model by NIH grantees explains why HIV prevention dosing differs by sex 2Health News:Allred Insurance Satellite Office Grand Opening 2Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 2Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 3Health News:Ebola Outbreak in Liberia May Be Slowing: WHO 2Health News:Ebola Outbreak in Liberia May Be Slowing: WHO 3Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 2Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 3Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 4Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 5
... City, Utah) University of Utah College of Nursing faculty ... Business Magazine today as one of its 2009 Health ... within the health care,system and contributes to continuously improving ... took place at the Grand America Hotel located in ...
... may be different in children and in H1N1 swine flu ... -- If you have the choice between a seasonal flu ... go for the injection, new research shows. , In a ... from inactivated, or "killed," flu virus -- the injectable form ...
... ATLANTA, Sept. 23 The Hospital of Central Connecticut (THOCC), a ... Practice Manager to automate, organize and increase quality of care ... at THOCC will be using IM,s handheld and Internet-based solution, joining ... making it the most widely used electronic charge capture system in ...
... , , SANTA MONICA, Calif., Sept. ... promoting critical thinking, created the new website http://healthcare.procon.org ... right (be entitled) to health care?" , , ... more than 14 million people nationwide. U.S. health expenditure totaled $2.2 ...
... cutting back on birth control to save money, survey finds, ... pregnancy and having fewer children because of the recession, but ... for it, a new survey finds. , "The recession has ... senior research associate at the Guttmacher Institute, which issued its ...
... New Delhi, Singapore and Washington DC (September23, 2009) SAGE ... launch Cartilage in 2010. A peer-reviewed quarterly journal, ... of ideas for the many types of researchers and clinicians ... journal of the ICRS, Cartilage is edited by ...
Cached Medicine News:Health News:U. College of Nursing's Kathie Supiano a 'health care hero' 2Health News:Injectable Vaccines More Effective for Adult Flu Than Nasal Sprays 2Health News:Injectable Vaccines More Effective for Adult Flu Than Nasal Sprays 3Health News:The Hospital of Central Connecticut Selects Ingenious Med for Inpatient Practice Management 2Health News:The Hospital of Central Connecticut Selects Ingenious Med for Inpatient Practice Management 3Health News:Right to Health Care Debated at New ProCon.org Website 2Health News:Recession Has Women Rethinking Childbearing 2Health News:Recession Has Women Rethinking Childbearing 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: